Hollencrest Capital Management Idera Pharmaceuticals, Inc. Transaction History

Hollencrest Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$0.23 - $0.43 $29,670 - $55,470	129,000 New	129,000 $45,000
Q2 2022 Jul 21, 2022	SELL	$0.32 - $0.74 $640 - $1,480	-2,000 Reduced 1.53%	129,000 $59,000
Q1 2022 Apr 18, 2022	SELL	$0.41 - $0.7 $6,150 - $10,500	-15,000 Reduced 10.27%	131,000 $66,000
Q4 2021 Jan 07, 2022	BUY	$0.53 - $1.03 $2,650 - $5,150	5,000 Added 3.55%	146,000 $84,000
Q1 2021 Apr 29, 2021	BUY	$1.23 - $5.98 $62,730 - $304,980	51,000 Added 56.67%	141,000 $183,000

Q3 2020 Oct 13, 2020	BUY	$1.71 - $2.68 $117,013 - $183,389	68,429 Added 317.23%	90,000 $192,000
Q4 2019 Jan 23, 2020	SELL	$1.45 - $2.79 $27,187 - $52,312	-18,750 Reduced 46.5%	21,571 $39,000
Q2 2019 Jul 18, 2019	BUY	$2.37 - $3.97 $44,437 - $74,437	18,750 Added 86.92%	40,321 $108,000
Q3 2018 Oct 04, 2018	BUY	$5.53 - $11.36 $119,287 - $245,046	21,571 New	21,571 $192,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

Stay updated on Hollencrest Capital Management with notifications on news.